argenx NV ADR (ARGX)vsNuCana PLC (NCNA)
ARGX
argenx NV ADR
$1,058.90
+1.13%
HEALTHCARE · Cap: $64.66B
NCNA
NuCana PLC
$1.47
-3.92%
HEALTHCARE · Cap: $6.33M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 32.3% profit margin vs 0.0%. NCNA trades at a lower P/E of 0.0x. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
NCNA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$2398.58
Current Price
$1058.90
$1339.68 discount
Intrinsic value data unavailable for NCNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 196.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : NCNA
The strongest argument for NCNA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : NCNA
The primary concerns for NCNA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while NCNA is a value play — different risk/reward profiles.
NCNA carries more volatility with a beta of 2.22 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (71/100 vs 26/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
NuCana PLC
HEALTHCARE · BIOTECHNOLOGY · USA
NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?